Passage Bio (PASG) Competitors $0.55 +0.03 (+6.21%) (As of 09:15 AM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends PASG vs. ALGS, VXRT, PYXS, TELO, MCRB, CRDF, SKYE, CRDL, CADL, and CGENShould you be buying Passage Bio stock or one of its competitors? The main competitors of Passage Bio include Aligos Therapeutics (ALGS), Vaxart (VXRT), Pyxis Oncology (PYXS), Telomir Pharmaceuticals (TELO), Seres Therapeutics (MCRB), Cardiff Oncology (CRDF), Skye Bioscience (SKYE), Cardiol Therapeutics (CRDL), Candel Therapeutics (CADL), and Compugen (CGEN). These companies are all part of the "pharmaceutical products" industry. Passage Bio vs. Aligos Therapeutics Vaxart Pyxis Oncology Telomir Pharmaceuticals Seres Therapeutics Cardiff Oncology Skye Bioscience Cardiol Therapeutics Candel Therapeutics Compugen Passage Bio (NASDAQ:PASG) and Aligos Therapeutics (NASDAQ:ALGS) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, profitability, media sentiment, community ranking, dividends, earnings and risk. Is PASG or ALGS more profitable? Passage Bio has a net margin of 0.00% compared to Aligos Therapeutics' net margin of -1,283.19%. Passage Bio's return on equity of -72.53% beat Aligos Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Passage BioN/A -72.53% -52.10% Aligos Therapeutics -1,283.19%-114.34%-64.58% Which has more volatility and risk, PASG or ALGS? Passage Bio has a beta of 1.2, suggesting that its share price is 20% more volatile than the S&P 500. Comparatively, Aligos Therapeutics has a beta of 2.11, suggesting that its share price is 111% more volatile than the S&P 500. Do institutionals and insiders hold more shares of PASG or ALGS? 53.5% of Passage Bio shares are held by institutional investors. Comparatively, 60.4% of Aligos Therapeutics shares are held by institutional investors. 4.3% of Passage Bio shares are held by insiders. Comparatively, 8.8% of Aligos Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Does the media prefer PASG or ALGS? In the previous week, Passage Bio had 4 more articles in the media than Aligos Therapeutics. MarketBeat recorded 5 mentions for Passage Bio and 1 mentions for Aligos Therapeutics. Aligos Therapeutics' average media sentiment score of 0.73 beat Passage Bio's score of -0.60 indicating that Aligos Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Passage Bio 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Negative Aligos Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts rate PASG or ALGS? Passage Bio currently has a consensus target price of $9.00, indicating a potential upside of 1,549.56%. Aligos Therapeutics has a consensus target price of $75.00, indicating a potential upside of 303.44%. Given Passage Bio's higher possible upside, equities analysts plainly believe Passage Bio is more favorable than Aligos Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Passage Bio 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00Aligos Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has stronger earnings & valuation, PASG or ALGS? Aligos Therapeutics has higher revenue and earnings than Passage Bio. Aligos Therapeutics is trading at a lower price-to-earnings ratio than Passage Bio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPassage BioN/AN/A-$102.06M-$1.17-0.47Aligos Therapeutics$15.53M4.30-$87.68M-$13.32-1.40 Does the MarketBeat Community believe in PASG or ALGS? Passage Bio received 24 more outperform votes than Aligos Therapeutics when rated by MarketBeat users. Likewise, 68.00% of users gave Passage Bio an outperform vote while only 65.85% of users gave Aligos Therapeutics an outperform vote. CompanyUnderperformOutperformPassage BioOutperform Votes5168.00% Underperform Votes2432.00% Aligos TherapeuticsOutperform Votes2765.85% Underperform Votes1434.15% SummaryPassage Bio beats Aligos Therapeutics on 10 of the 16 factors compared between the two stocks. Ad Porter & CompanyFinancial Prophecy The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold $3 billion of Amazon… it’s why Nvidia’s CEO just sold $713 million... and it’s why Zuckerberg just sold $1.3 billion in Meta stock. The financial establishment doesn’t want you to know about this… but a controversial new documentary just pulled back the curtain and exposed what’s really going on. It’s called The Final Frontier.Including the name of the #1 company to buy. Get Passage Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for PASG and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PASG vs. The Competition Export to ExcelMetricPassage BioBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$33.70M$2.93B$5.07B$8.90BDividend YieldN/A1.91%4.99%4.07%P/E Ratio-0.4716.1687.8613.46Price / SalesN/A282.771,228.8287.66Price / CashN/A169.3839.5136.27Price / Book0.464.436.946.30Net Income-$102.06M-$41.63M$119.12M$225.93M7 Day Performance-7.56%-4.73%-1.84%-1.32%1 Month Performance-7.29%-6.53%-3.65%0.60%1 Year Performance-12.00%25.63%31.64%26.23% Passage Bio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PASGPassage Bio2.9528 of 5 stars$0.55+6.2%$9.00+1,549.6%-19.0%$33.70MN/A-0.47130ALGSAligos Therapeutics4.1561 of 5 stars$18.59+2.1%$75.00+303.4%+5.5%$66.74M$15.53M-1.3790VXRTVaxart2.1372 of 5 stars$0.61-0.5%$3.00+395.9%-22.1%$107.35M$7.38M-1.48109Analyst RevisionNews CoveragePYXSPyxis Oncology1.0178 of 5 stars$2.25-41.1%$9.57+325.4%+165.3%$133.81MN/A-3.7160News CoverageGap UpHigh Trading VolumeTELOTelomir PharmaceuticalsN/A$4.50+7.1%N/AN/A$133.25MN/A0.001News CoverageMCRBSeres Therapeutics3.8903 of 5 stars$0.78-4.2%$5.08+551.6%-16.1%$133.19M$126.32M0.00233Analyst UpgradeCRDFCardiff Oncology1.0829 of 5 stars$2.59+2.4%$9.33+260.4%+118.1%$132.43M$490,000.000.0020SKYESkye Bioscience1.2915 of 5 stars$4.28-1.4%$18.67+336.1%+152.9%$131.67MN/A0.0011Insider TradeCRDLCardiol Therapeutics2.7365 of 5 stars$1.59+1.9%$8.75+450.3%+81.1%$129.74M$60,000.00-4.0020Analyst ForecastAnalyst RevisionNews CoverageCADLCandel Therapeutics1.8165 of 5 stars$3.97-0.3%$11.00+177.1%+347.1%$128.95M$120,000.000.0060Analyst ForecastAnalyst RevisionNews CoverageCGENCompugen2.7226 of 5 stars$1.44+0.7%$4.00+177.8%+121.5%$128.51M$33.46M71.5068 Related Companies and Tools Related Companies ALGS Alternatives VXRT Alternatives PYXS Alternatives TELO Alternatives MCRB Alternatives CRDF Alternatives SKYE Alternatives CRDL Alternatives CADL Alternatives CGEN Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:PASG) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | SponsoredBut another coin could soar even higher …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin co...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Passage Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Passage Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
